Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients
Aim. Noninvasive identification of haemodialysis patients at high risk of cardiovascular events and death might improve their outcome. Growth differentiation factor 15 is a prognostic biomarker in multiple disease entities, including cardiovascular disease. The aim of this study was to assess the as...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2023/5163548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547887648604160 |
|---|---|
| author | Christelle Calen Seraina Von Moos Pietro Cippà Alexandre Mebazaa Mattia Arrigo |
| author_facet | Christelle Calen Seraina Von Moos Pietro Cippà Alexandre Mebazaa Mattia Arrigo |
| author_sort | Christelle Calen |
| collection | DOAJ |
| description | Aim. Noninvasive identification of haemodialysis patients at high risk of cardiovascular events and death might improve their outcome. Growth differentiation factor 15 is a prognostic biomarker in multiple disease entities, including cardiovascular disease. The aim of this study was to assess the association between plasma GDF-15 and mortality in a cohort of haemodialysis patients. Methods. Circulating GDF-15 was measured in 30 patients after a regular haemodialysis session, followed by a clinical follow-up for all-cause death. Measurements were performed using the Proseek Multiplex Cardiovascular disease panels (Olink Proteomics AB) and validated using the Elecsys GDF-15 electrochemiluminescence immunoassay on a Cobas E801 analyzer (Roche Diagnostics). Results. During a median of 38 months, 9 patients (30%) died. Seven deaths occurred in the group of patients with a circulating GDF-15 above the median and two in the group with lower GDF-15. Mortality was significantly higher in patients with circulating GDF-15 levels above the median, log-rankP = 0.044. The performance of circulating GDF-15 to predict long-term mortality has an area under the ROC curve of 0.76, P = 0.028. Prevalence of most relevant comorbidities and the Charlson comorbidity index were similar across the two groups. A high agreement with a correlation among both diagnostic methods was observed (Spearman’s rho = 0.83, P<0.001). Conclusion. Plasma GDF-15 displays promising prognostic properties for the prediction of long-term survival beyond clinical parameters in patients on maintenance haemodialysis. |
| format | Article |
| id | doaj-art-f54f780bbecf4ba7878f90d833804213 |
| institution | Kabale University |
| issn | 2090-2158 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-f54f780bbecf4ba7878f90d8338042132025-02-03T06:43:14ZengWileyInternational Journal of Nephrology2090-21582023-01-01202310.1155/2023/5163548Growth Differentiation Factor 15 and Risk of Death in Haemodialysis PatientsChristelle Calen0Seraina Von Moos1Pietro Cippà2Alexandre Mebazaa3Mattia Arrigo4Division of General Internal MedicineDepartment of NephrologyDivision of NephrologyDepartment of Critical Care and AnesthesiologyDepartment of Internal MedicineAim. Noninvasive identification of haemodialysis patients at high risk of cardiovascular events and death might improve their outcome. Growth differentiation factor 15 is a prognostic biomarker in multiple disease entities, including cardiovascular disease. The aim of this study was to assess the association between plasma GDF-15 and mortality in a cohort of haemodialysis patients. Methods. Circulating GDF-15 was measured in 30 patients after a regular haemodialysis session, followed by a clinical follow-up for all-cause death. Measurements were performed using the Proseek Multiplex Cardiovascular disease panels (Olink Proteomics AB) and validated using the Elecsys GDF-15 electrochemiluminescence immunoassay on a Cobas E801 analyzer (Roche Diagnostics). Results. During a median of 38 months, 9 patients (30%) died. Seven deaths occurred in the group of patients with a circulating GDF-15 above the median and two in the group with lower GDF-15. Mortality was significantly higher in patients with circulating GDF-15 levels above the median, log-rankP = 0.044. The performance of circulating GDF-15 to predict long-term mortality has an area under the ROC curve of 0.76, P = 0.028. Prevalence of most relevant comorbidities and the Charlson comorbidity index were similar across the two groups. A high agreement with a correlation among both diagnostic methods was observed (Spearman’s rho = 0.83, P<0.001). Conclusion. Plasma GDF-15 displays promising prognostic properties for the prediction of long-term survival beyond clinical parameters in patients on maintenance haemodialysis.http://dx.doi.org/10.1155/2023/5163548 |
| spellingShingle | Christelle Calen Seraina Von Moos Pietro Cippà Alexandre Mebazaa Mattia Arrigo Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients International Journal of Nephrology |
| title | Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients |
| title_full | Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients |
| title_fullStr | Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients |
| title_full_unstemmed | Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients |
| title_short | Growth Differentiation Factor 15 and Risk of Death in Haemodialysis Patients |
| title_sort | growth differentiation factor 15 and risk of death in haemodialysis patients |
| url | http://dx.doi.org/10.1155/2023/5163548 |
| work_keys_str_mv | AT christellecalen growthdifferentiationfactor15andriskofdeathinhaemodialysispatients AT serainavonmoos growthdifferentiationfactor15andriskofdeathinhaemodialysispatients AT pietrocippa growthdifferentiationfactor15andriskofdeathinhaemodialysispatients AT alexandremebazaa growthdifferentiationfactor15andriskofdeathinhaemodialysispatients AT mattiaarrigo growthdifferentiationfactor15andriskofdeathinhaemodialysispatients |